drugset / Trial / NCT00546663

Tolerability of Inhaled Hypertonic Saline in Infants With Cystic Fibrosis

NCT00546663

NaSingle-groupOpen-labelTreatment

Summary

This is an open-label pilot study of the safety and tolerability of 7% hypertonic saline inhaled twice daily for 14 days in infants with CF, 12 to 30 months of age.

Timeline

Start
2007-09
Primary completion
2008-05
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Hypertonic saline Unknown 7 % Inhaled

Indications